Uni Eropa - Italia - EMA (European Medicines Agency)

bayer animal health gmbh - iron(iii) ion, toltrazuril - toltrazuril, combinazioni di - maiali - per la concomitante prevenzione dei segni clinici della coccidiosi (come la diarrea) neonatale suinetti di aziende agricole con un confermato che la storia della coccidiosi causato da cystoisospora suis, e la prevenzione di anemia da carenza di ferro.

Uni Eropa - Italia - EMA (European Medicines Agency)

qbiotics netherlands b.v. - tigilanol caprato - tigilanol caprato - cani - per il trattamento di non-resecabile, camere non-metastatico (che stadiazione) per via sottocutanea tumori delle cellule dell'albero si trova in corrispondenza o distale per il gomito o il garretto, e non resecabile, non metastasi cutanee di mastociti tumori nei cani.

Uni Eropa - Italia - EMA (European Medicines Agency)

vetoquinol - tulatromicina - antibatterici per uso sistemico - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. la presenza della malattia nella mandria deve essere stabilita prima del trattamento metafilattico. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. la presenza della malattia nella mandria deve essere stabilita prima del trattamento metafilattico. the product should only be used if pigs are expected to develop the disease within 2–3 days. pecora: trattamento delle prime fasi di pododermatite infettiva (marciume del piede) associata a dichelobacter nodosus virulento che richiede un trattamento sistemico.

Uni Eropa - Italia - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccini - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali.

Uni Eropa - Italia - EMA (European Medicines Agency)

elanco gmbh - tulatromicina - antibatterici per uso sistemico - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. la presenza della malattia nella mandria deve essere stabilita prima del trattamento metafilattico. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. la presenza della malattia nella mandria deve essere stabilita prima del trattamento metafilattico. the product should only be used if pigs are expected to develop the disease within 2–3 days. pecora: trattamento delle prime fasi di pododermatite infettiva (marciume del piede) associata a dichelobacter nodosus virulento che richiede un trattamento sistemico.

Uni Eropa - Italia - EMA (European Medicines Agency)

vmd n.v. - tulatromicina - antibacterials for systemic use, macrolides - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. la presenza della malattia nella mandria deve essere stabilita prima del trattamento metafilattico. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. la presenza della malattia nella mandria deve essere stabilita prima del trattamento metafilattico. the product should only be used if pigs are expected to develop the disease within 2–3 days. pecora: trattamento delle prime fasi di pododermatite infettiva (marciume del piede) associata a dichelobacter nodosus virulento che richiede un trattamento sistemico.

Uni Eropa - Italia - EMA (European Medicines Agency)

dechra regulatory b.v. - tulatromicina - antibatterici per uso sistemico - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. la presenza della malattia nella mandria deve essere stabilita prima del trattamento metafilattico. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. la presenza della malattia nella mandria deve essere stabilita prima del trattamento metafilattico. the product should only be used if pigs are expected to develop the disease within 2–3 days. pecora: trattamento delle prime fasi di pododermatite infettiva (marciume del piede) associata a dichelobacter nodosus virulento che richiede un trattamento sistemico.

Uni Eropa - Italia - EMA (European Medicines Agency)

serb sa - amifampridine phosphate - lambert-eaton myasthenic syndrome; paraneoplastic syndromes, nervous system; nervous system neoplasms; paraneoplastic syndromes; nervous system diseases; autoimmune diseases of the nervous system; neurodegenerative diseases; neuromuscular diseases; neuromuscular junction diseases; immune system diseases; autoimmune diseases; autoimmune diseases of the nervous system; cancer; neoplasms - altri farmaci sul sistema nervoso - trattamento sintomatico della sindrome miastenica di lambert-eaton (lems) negli adulti.

Uni Eropa - Italia - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - emofilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

Italia - Italia - Ministero della Salute

ivoclar vivadent ag - adesivi per odontoiatria